PMEDAP

Research use only, not for human use.

PMEDAP is a potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality and an inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP also has anti-murine cytomegalovirus (MCMV) activity.

PMEDAP is a potent inhibitor of Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality and an inhibitor of human immunodeficiency virus (HIV) replication. PMEDAP also has anti-murine cytomegalovirus (MCMV) activity.(In Vivo):In Three-week-old male NMRI mice inoculated with MSV, PMEDAP (0.25-5 mg/kg; IP; daily;) effected a significant delay in tumor appearance and an enhancement of the survival rate of tumor-bearing mice. PMEDAP also suppressed tumor formation and mortality in a dose-dependent manner.

——

PMEDAP (0.25-5 mg/kg; IP; daily; starting on the day of MSV-infected and continuing for an additional four days) causes a dose-dependent suppression of tumor formation and mortality in newborn mice inoculated with MSV. Animal Model:Three-week-old male NMRI mice Dosage:0.25 mg/kg, 1 mg/kg, 5 mg/kg Administration:IP; daily; starting on the day of infection and continuing for an additional four days Result:Effected a significant delay in tumor appearance and an enhancement of the survival rate of tumor-bearing mice.

——

Others

Other Targets

——

——

——

113852-41-8

288.2

C8H13N6O4P

>98% (HPLC)

In Vitro:?0.1 M NaOH : 14.29 mg/mL (49.)

Nc1c2ncn(CCOCP(O)(O)=O)c2nc(N)n1

——

(-20℃)

With Ice Pack

≥ 2 years